Tracking the body’s secrets: the power of nuclear medicine
For decades, medicine looked at the anatomy of the human body, observed at a single moment in time. Traditional imaging techniques, like X-rays, captured static images, revealing shapes and structures. It showed visible abnormalities but did not explain the underlying causes.
Nuclear medicine is something different than common medicine. You cannot touch it. Instead of looking at anatomy, nuclear medicine follows the clues inside the body, tracking biological processes. This molecular pursuit provides real-time insights into the behavior of organs, tissues, and cells.
This investigation is made possible by radiopharmaceuticals. Once introduced inside the body, they become part of normal biological processes, travel to specific targets, and emit radiation that detectors can read from outside the body and create images of biological processes happening in real time with PET or SPECT scan. It allows clinicians to precisely locate where abnormal activity occurs.
By focusing on function rather than just anatomy, nuclear medicine enables earlier diagnosis, guides treatment decisions, and monitors how the body responds.
Beyond diagnosis, nuclear medicine is increasingly used to treat diseases directly, delivering targeted therapies to affected cells while sparing healthy tissue.
Why does it matter?
Because precision is everything in medicine. One of the biggest challenges in oncology has always been: how can we destroy a cancer cell without destroying the healthy tissue around it?
Nuclear medicine answers with precision. It doesn’t flood the whole body with a drug; it sends a molecule to a specific target and emits radiation on the right tissues.
Over the past decade, nuclear medicine has moved from the periphery of oncology to its centre stage. Major pharmaceutical companies have entered the field. Clinical pipelines that didn't exist five years ago are now in late-phase trials.
Why is theranostic approach a key factor for patients?
- Higher specificity
The radioisotope goes where it's needed.
- Lower collateral damage
Surrounding healthy tissue is spared.
- Earlier and more accurate diagnosis
Catching disease at a stage where treatment is still highly effective.
- Personalized treatment selection
Imaging first, therapy second, with the same molecular logic guiding both.
The challenges ahead
The field is growing fast. But growth brings challenges:
- Workforce: Nuclear medicine specialists’ demand is outpacing supply globally. Training pipelines built for a smaller field are now serving a rapidly expanding one.
- Regulatory: As new isotopes and new targeting molecules enter clinical use, regulatory frameworks are evolving. Harmonization across regions remains a significant challenge.
- Access: Technology exists and the clinical evidence is being built but not every hospital, not every country has equal access to cyclotrons, isotopes or trained professionals. There is a gap between what is scientifically possible and what is clinically available worldwide.
- Healthcare industry: Major pharmaceutical companies are now investing heavily in radiopharmaceuticals. This accelerates timelines and brings capital but it raises the bar for smaller players and creates questions about market dynamics and access.
Learn from Expert Spotlights
Discover the main trends in nuclear medicine with the inspiring interview of Prof Dr Rudi Dierckx, Past President of the European Association of Nuclear Medicine (EANM, 2023-2024).